[go: up one dir, main page]

BRPI0915240A2 - método para tratar câncer, método para avaliação de um paciente submetido ao tratamento de câncer, método para avaliação de um paciente que tem ou com suspeita de ter câncer e uso de um anticorpo anti-c-met - Google Patents

método para tratar câncer, método para avaliação de um paciente submetido ao tratamento de câncer, método para avaliação de um paciente que tem ou com suspeita de ter câncer e uso de um anticorpo anti-c-met

Info

Publication number
BRPI0915240A2
BRPI0915240A2 BRPI0915240A BRPI0915240A BRPI0915240A2 BR PI0915240 A2 BRPI0915240 A2 BR PI0915240A2 BR PI0915240 A BRPI0915240 A BR PI0915240A BR PI0915240 A BRPI0915240 A BR PI0915240A BR PI0915240 A2 BRPI0915240 A2 BR PI0915240A2
Authority
BR
Brazil
Prior art keywords
evaluating
cancer
patient
met antibody
suspected
Prior art date
Application number
BRPI0915240A
Other languages
English (en)
Inventor
Amy C Peterson
Arthur E Ii Reyes
Brendan C Bender
Hong Xiang
Mark Merchant
Nelson L Jumbe
Priti Hegde
Steve Eppler
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41491698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0915240(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0915240A2 publication Critical patent/BRPI0915240A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0915240A 2008-10-17 2009-10-14 método para tratar câncer, método para avaliação de um paciente submetido ao tratamento de câncer, método para avaliação de um paciente que tem ou com suspeita de ter câncer e uso de um anticorpo anti-c-met BRPI0915240A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10649508P 2008-10-17 2008-10-17
US15257009P 2009-02-13 2009-02-13
PCT/US2009/060662 WO2010045345A2 (en) 2008-10-17 2009-10-14 Treatment method

Publications (1)

Publication Number Publication Date
BRPI0915240A2 true BRPI0915240A2 (pt) 2016-02-16

Family

ID=41491698

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915240A BRPI0915240A2 (pt) 2008-10-17 2009-10-14 método para tratar câncer, método para avaliação de um paciente submetido ao tratamento de câncer, método para avaliação de um paciente que tem ou com suspeita de ter câncer e uso de um anticorpo anti-c-met

Country Status (14)

Country Link
US (1) US20110262436A1 (pt)
EP (1) EP2344543A2 (pt)
JP (1) JP2012505904A (pt)
KR (1) KR20110069092A (pt)
CN (1) CN102216331A (pt)
AR (1) AR073853A1 (pt)
AU (1) AU2009303392A1 (pt)
BR (1) BRPI0915240A2 (pt)
CA (1) CA2739302A1 (pt)
IL (1) IL212348A0 (pt)
MX (1) MX2011004050A (pt)
RU (1) RU2011119638A (pt)
TW (1) TW201022214A (pt)
WO (1) WO2010045345A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513427A (ja) * 2008-03-06 2011-04-28 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法
MX2012012992A (es) * 2010-05-14 2012-12-17 Genentech Inc Metodos de tratamiento.
RU2013114360A (ru) 2010-08-31 2014-10-10 Дженентек, Инк. Биомаркеры и способы лечения
ES2609578T3 (es) 2011-03-04 2017-04-21 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
US20130004484A1 (en) * 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
TWI547494B (zh) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
CN104066748A (zh) 2011-11-21 2014-09-24 霍夫曼-拉罗奇有限公司 抗c-met抗体的纯化
KR20150008171A (ko) * 2012-05-10 2015-01-21 자임워크스 인코포레이티드 단일군 일가 항체 구조물 및 그의 용도
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
KR101911048B1 (ko) 2013-01-29 2018-10-24 삼성전자주식회사 ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물
AR094707A1 (es) 2013-02-21 2015-08-19 Glaxosmithkline Ip Dev Ltd Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
KR102029137B1 (ko) 2013-03-27 2019-10-08 삼성전자주식회사 EGFR 길항제 및 항 c-Met 항체를 포함하는 병용 투여용 약학 조성물
EP2786764B1 (en) 2013-04-01 2017-03-08 Samsung Electronics Co., Ltd. Combination therapy using anti-c-met antibody and sorafenib
CN104211814A (zh) * 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015085233A1 (en) * 2013-12-06 2015-06-11 The Broad Institute Inc. Formulations for neoplasia vaccines
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
EP2891884B1 (en) * 2014-01-07 2017-10-25 Samsung Electronics Co., Ltd IL-8 for predicting or monitoring efficacy of c-MET inhibitor
KR102194142B1 (ko) * 2014-01-20 2020-12-23 삼성전자주식회사 항 c-Met/항 EGFR 이중 특이 항체 및 c-Src 저해제를 포함하는 병용 투여용 약학 조성물
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR102338678B1 (ko) * 2014-04-03 2021-12-13 삼성전자주식회사 항 c-Met 항체 효과 예측을 위한 바이오마커
EP2937421B1 (en) * 2014-04-03 2018-10-24 Samsung Electronics Co., Ltd Biomarker for predicting effect of an anti-C-met antibody
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
CR20230191A (es) 2015-05-20 2023-07-06 Dana Farber Cancer Inst Inc NEOANTIGENOS COMPARTIDOS (Div. exp 2017-584)
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN121015920A (zh) 2019-09-16 2025-11-28 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US11866493B2 (en) * 2019-11-01 2024-01-09 East Tennessee State University Research Foundation Single-chain variable fragment of Met monoclonal antibody and methods of use in CAR T cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9805398A (en) * 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
AU2007245181A1 (en) * 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-Met
JP2011513427A (ja) * 2008-03-06 2011-04-28 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法
WO2009111707A1 (en) * 2008-03-06 2009-09-11 Genentech, Inc. Combination therapy with c-met and her antagonists

Also Published As

Publication number Publication date
WO2010045345A2 (en) 2010-04-22
CA2739302A1 (en) 2010-04-22
AR073853A1 (es) 2010-12-09
WO2010045345A3 (en) 2010-09-10
JP2012505904A (ja) 2012-03-08
AU2009303392A1 (en) 2010-04-22
KR20110069092A (ko) 2011-06-22
RU2011119638A (ru) 2012-11-27
IL212348A0 (en) 2011-06-30
TW201022214A (en) 2010-06-16
EP2344543A2 (en) 2011-07-20
CN102216331A (zh) 2011-10-12
US20110262436A1 (en) 2011-10-27
MX2011004050A (es) 2011-05-10

Similar Documents

Publication Publication Date Title
BRPI0915240A2 (pt) método para tratar câncer, método para avaliação de um paciente submetido ao tratamento de câncer, método para avaliação de um paciente que tem ou com suspeita de ter câncer e uso de um anticorpo anti-c-met
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
BRPI0921687A2 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
WO2010025414A3 (en) Diagnostics and treatments for vegf-independent tumors
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
BRPI0917189A2 (pt) dispositivo para uso em tratamento cirúrgico de tórax em funil e método de tratamento.
CR10667A (es) Compositions and methods for diagnosing and treating cancer
BRPI0906903A2 (pt) ''anticorpo kit de diagnóstico, método de detecção da expressão de cd70 em uma amostra de tecido, método para prognosticar, determinar um protocolo de tratamento ou monitorar o tratamento, uso de um agente de ligação a cd70 e combinação de um kit de diagnóstico e um kit farmacêutico
BR112013000745A2 (pt) "método para diagnosticar ou detectar câncer colorretal em um individuo, método de tratamento e método para monitorar a eficacia de tratamento de câncer colorretal em um indivíduo"
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
WO2013063155A3 (en) Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
BR122018069446B8 (pt) método in vitro para detectar a presença de um célula de câncer em um indivíduo
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
EP2293062A4 (en) BLOOD ANALYSIS DEVICE, BLOOD ANALYSIS METHOD, HEMOLYTIC AGENT, AND COLORING AGENT
EP1991701A4 (en) COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
CY1116019T1 (el) Μεθοδος χρησης καταστολεων histone deacetylase και παρακολουθηση παραγοντων βιο-σημανσης σε θεραπεια συνδυασμου
BR112012009315A2 (pt) gantry compreendendo um analisador de feixes, para o uso em terapias com partículas
BRPI0818437B8 (pt) anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
BRPI0923630A2 (pt) sistemas e métodos de processamento e incorporação de amostras de tecido para biópsia durante processo de histopalogia e de realização de pelo menos parte do mesmo.
BRPI0906244A2 (pt) Composto, composição farmacêutica, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissores ou um distúrbio neuronal em um indivíduo, uso de um composto e kit
BRPI0910030A2 (pt) método de teste ultra-sônico e equipamento para o mesmo.
BR112013014522A2 (pt) anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
BRPI0917257A2 (pt) sistema, e método para liberar um componente em uma zona de um poço ou próxima a um poço
BRPI0817328A2 (pt) Método e aparelho para tratamento de resíduo orgânico.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]